Earnings call transcript: HealthCo posts mixed H2 2026 results as Healthscope drag continues

HealthCo (HCW) ended FY26 with reported FFO of AUD 0.04/unit (distorted by suspended distributions from the unlisted healthcare fund), versus underlying look-through FFO of AUD 0.077/unit. The company did not declare a FY26 distribution and guided FY27 to underlying FFO of AUD 0.061/unit and DPU of AUD 0.06/unit, pending resolution of the Healthscope hospital transition (10 remaining hospitals). Shares were unchanged at $0.72, reflecting a wait-and-see stance amid distribution-timing uncertainty, even as rent collection was 100% and occupancy averaged 99% with gearing at 29% and cash of AUD 158m.

Analysis

This is less a property earnings story than a cash-flow visibility trade. The portfolio itself looks stable enough that the equity should ultimately trade on duration and governance risk, not on near-term occupancy or rent collection; the discount exists because distributions are trapped behind an unresolved transition, and yield buyers won’t pay up until that cash is demonstrably portable. The next leg higher is therefore not driven by reported FFO; it requires a credible timetable for lease novations and a first post-transition cash payment.

The second-order dynamic is that tenant diversification could improve the asset multiple even if near-term economics look slightly worse. If the replacement leases are truly sticky, the market should be willing to assign a lower cap-rate premium and a lower required yield to the portfolio over 6-18 months, especially with leverage already modest. But the flip side is that any incentive-heavy lease structure can keep headline NOI flat while masking a weaker sustainable payout rate, so the market may stay skeptical until it sees actual cash distributions, not just valuation language.

Contrarian view: the market may be underestimating how much of the rerating is blocked by timing, not value. Book value and replacement cost are useful anchors, but in a higher-rate regime they do not protect the unit price if the distribution stream remains uncertain for another quarter or two. The bear case is a prolonged approval process or a worse-than-advertised incentive package; the bull case is a clean October transition followed by a restart in distributions, which could compress the discount to NTA quickly.

Key Decisions for Investors

• If we can trade HCW.ASX, wait for receiver approval on the remaining hospitals before initiating size; a post-approval close above A$0.75 would be the cleaner entry for a 3-month move toward A$0.82-A$0.85. Falsifier: delay beyond 4Q26 or FY27 DPU slipping below A$0.06.
• For existing exposure, hedge the idiosyncratic execution risk with a short VAP.AX basket hedge rather than exiting outright; this keeps real-estate beta neutral while the legal/process risk resolves.
• Treat the October Mount Hospital transition as the first real catalyst, not the FY26 results; add only on confirmation of a clean handover and a visible path to the first cash distribution.
• Do not extrapolate this into a broad healthcare REIT overweight yet; wait for actual post-transition cash flows before adding sector beta.
• If management announces a special or catch-up distribution after resolution, that is the signal to reassess for a faster re-rating; absent that, expect the stock to remain range-bound.